What Next for Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) Stock After Increase in Shorted Shares?

The stock of Foamix Pharmaceuticals LTD. – Ordinary Shares (NASDAQ:FOMX) registered an increase of 9.7% in short interest. FOMX’s total short interest was 1.65 million shares in March as published by FINRA. Its up 9.7% from 1.50 million shares, reported previously. With 319,500 shares average volume, it will take short sellers 5 days to cover their FOMX’s short positions. The short interest to Foamix Pharmaceuticals LTD. – Ordinary Shares’s float is 4.51%.

The stock decreased 2.73% or $0.11 during the last trading session, reaching $3.92. About 295,177 shares traded. Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has declined 36.97% since March 15, 2018 and is downtrending. It has underperformed by 41.34% the S&P500.

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular, rosacea, and other skin conditions in the United States, Germany, and France. The company has market cap of $213.12 million. The Company’s lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. It currently has negative earnings. The firm is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Coverage

Among 4 analysts covering Foamix Pharma (NASDAQ:FOMX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Foamix Pharma had 7 analyst reports since November 27, 2018 according to SRatingsIntel. H.C. Wainwright maintained Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) rating on Monday, March 4. H.C. Wainwright has “Buy” rating and $12 target. The firm earned “Buy” rating on Wednesday, February 27 by Cantor Fitzgerald. The firm earned “Buy” rating on Tuesday, November 27 by Cantor Fitzgerald. The rating was maintained by Cowen & Co on Friday, March 1 with “Buy”. The stock of Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) has “Buy” rating given on Friday, March 8 by Cantor Fitzgerald.

More notable recent Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) news were published by: Seekingalpha.com which released: “Foamix Pharma +54% as acne drug meets goals in late-stage trial – Seeking Alpha” on September 11, 2018, also Benzinga.com with their article: “64 Stocks Moving In Friday’s Mid-Day Session – Benzinga” published on March 01, 2019, Seekingalpha.com published: “FDA accepts Foamix NDA for acne treatment FMX101; shares up 4% premarket – Seeking Alpha” on March 07, 2019. More interesting news about Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) were released by: Globenewswire.com and their article: “Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne – GlobeNewswire” published on December 21, 2018 as well as Seekingalpha.com‘s news article titled: “Foamix Is Headed For Dilution – Seeking Alpha” with publication date: September 14, 2018.

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.